Are you worried we’re missing the point with new weight loss drugs and getting into an arms race with big food and big pharma. Join us as we launch our weight loss drug consensus statement and talk about the wrap-around Lifestyle Medicine care that is needed to ensure safe, effective and sustainable weight loss. Dr Fallows is Vice-President of the BSLM, an obesity and lifestyle medicine expert and researcher at the Leeds Beckett Institute of Obesity. She will share her experiences supporting people who rapidly lose weight in the NHS Paths to Remission low-calorie total diet replacement programme and people who are prescribed the new GLP1/GIP medications. You’ll hear more about some of the potential unintended consequences and why Lifestyle Medicine qualifications will be critical for a safe roll-out.
Are you ready for the NHS roll-out of weight-loss drug tirzepatide (Mounjaro) to 2.8 million patients 1? Learn more about how best to support people using these medications with a Lifestyle Medicine approach that addresses the root causes of obesity to ensure safe, effective and sustainable weight loss. Dr Fallows is Vice-President of the BSLM, an obesity and lifestyle medicine expert and researcher at the Leeds Beckett Institute of Obesity. She will share her experiences supporting people who rapidly lose weight in the NHS Paths to Remission low-calorie total diet replacement programme and people who are prescribed the new GLP1/GIP medications. You’ll hear more about some of the potential unintended consequences and why Lifestyle Medicine qualifications will be critical for a safe roll-out
Click Here to Register!
